Oncology Venture AB was formed in 2012 by Danish and US oncology specialists and business people dedicated to unlock the potential of oncology products that has shown efficacy but not enough to beat the gold standard - to improve the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and through this improve success rates in Oncology Drug Development.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Sass & Larsen ApS | 15,03 | 15,03 | 2018-06-30 |
| Buhl Krone Holding ApS | 9,28 | 9,28 | 2018-06-30 |
| Leon Sass | 3,20 | 3,20 | 2018-06-30 |
| Viggo Harboe 2006 Holding ApS | 3,05 | 3,05 | 2018-06-30 |
| Avanza Pension | 1,77 | 1,77 | 2018-06-30 |
| Greven Dental AB | 1,27 | 1,27 | 2018-06-30 |
| Lennart Nordevall | 1,02 | 1,02 | 2018-06-30 |
| Nordnet Pensionsförsäkring | 0,78 | 0,78 | 2018-06-30 |
| Sparekassen Kronjylland - General Client Account | 0,75 | 0,75 | 2018-06-30 |
| Patrick Sass | 0,66 | 0,66 | 2018-06-30 |
